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Abstract 
Repositories containing high quality human biospecimens linked with robust and relevant 
clinical and pathological information are required for the discovery and validation of 
biomarkers for disease diagnosis, progression and response to treatment.  Current molecular 
based discovery projects using either low or high throughput technologies rely heavily on 
ready access to such sample collections.  It is imperative that modern biobanks align with 
molecular diagnostic pathology practices not only to provide the type of samples needed for 
discovery projects but also to ensure requirements for ongoing sample collections and the 
future needs of researchers are adequately addressed.  Biobanks within comprehensive 
molecular pathology programmes are perfectly positioned to offer more than just tumour 
derived biospecimens; for example, they have the ability to facilitate researchers gaining 
access to sample metadata such as digitised scans of tissue samples annotated prior to 
macrodissection for molecular diagnostics or pseudoanonymised clinical outcome data or 
research results retrieved from other users utilising the same or overlapping cohorts of 
samples. Furthermore, biobanks can work with molecular diagnostic laboratories to develop 
standardized methodologies for the acquisition and storage of samples required for new 
approaches to research such as ‘liquid biopsies’ which will ultimately feed into the test 
validations required in large prospective clinical studies in order to implement liquid biopsy 
approaches for routine clinical practice.  We draw on our experience in Northern Ireland to 
discuss how this harmonised approach of biobanks working synergistically with molecular 
pathology programmes is key for the future success of precision medicine. 
 
Keywords: biobank, tissue bank, molecular pathology, digital pathology, informatics, 
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molecular diagnostics  
Introduction 
 
Increased understanding of molecular and genetic mechanisms of disease has transformed 
treatment, prediction and diagnosis of cancer.  Advances in proteomics and genomics such as 
mass spectrometry to simultaneously detect and characterise proteins and peptides, and next 
generation sequencing (NGS) for complete genome interrogation have had a profound shift 
in the ability of medicine to deliver on the promise of targeted therapies for patients with 
cancer [1,2]. Underpinning this shift is an increase in translational research activity which is 
heavily reliant on large numbers of high quality human biospecimens (tissues, blood and other 
bodily fluids) linked with reliable clinical and pathological data.  In order to make such samples 
available for research, ‘biobanking’ has become the conduit for the standardised collection, 
storage and distribution of human samples; in turn maximising biospecimen quality but also 
meeting many of the legal and ethical challenges for the use of human specimens in research. 
[3] Biobanks are now recognised as the cornerstone of biomarker discovery and personalized 
medicine. [4]. However, in an environment where science is developing rapidly and where the 
conventional model for drug discovery and diagnostics is constantly challenged, it is 
important to explore how biobanks may be best integrated into existing operations for tissue 
based translational research.   
 
Molecular Pathology has emerged as an integrated discipline defining the relationship 
between genotype and phenotype, between basic molecular mechanisms and clinical 
applications and between bench and bedside, all factors at the core of a successful 
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translational research programme. [5] Precision or stratified medicine is thus the application 
of predictive molecular pathology using conventional methodologies and /or high throughput 
analytical methods on human biospecimens to indicate the efficacy of a drug for an individual 
patient.  With this article we propose that biobanks are an integral part of a successful modern 
molecular pathology programme (Figure 1) and are necessary to facilitate scientific discovery, 
advance research and meet the needs of the surrounding research community.  Drawing on 
our experience in a Northern Ireland based biobank, we discuss how biobanking has synergy 
with other components of a molecular pathology programme, and how integration best 
creates a sustainable, affordable translational research infrastructure resulting in a repository 
not of samples but rather a repository of science.  
 
*Insert FIGURE 1 here* 
 
Biobanks 
 
Prospective and Retrospective Sample Collection: Repositories containing high quality 
biospecimens linked with robust and relevant clinical and pathological information are 
required for the discovery and validation of biomarkers for disease diagnosis, progression and 
response to treatment. Ready access to such material is fundamental for meaningful 
translational research.  In the case of cancer research, tumour banks have been established 
to procure fresh as well as formalin-fixed, paraffin-embedded (FFPE) tumour tissues and non-
tumour control samples. These tissue collections are increasingly complemented by matched 
samples of blood, urine, saliva and other bodily fluids where appropriate.  Despite a significant 
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proportion of research in genomics and proteomics requiring the availability of fresh and/or 
fresh frozen tissues[6], recent studies have demonstrated comparable NGS results for both 
FFPE and fresh frozen tissue when fixed according to a standardised protocol[7,8]. Whilst the 
authors caution that amplicon length needs to be taken into consideration when developing 
NGS gene panels for use with FFPE, it is expected that FFPE will become an increasingly 
attractive resource for high throughput platforms.  
 
While prospectively targeted collections of appropriately consented human samples are the 
ideal for translational research programmes, realistically the systematic accumulation of large 
numbers of samples linked to clinical follow up, apart from being costly, may take many years 
to become established. Yet readily available resources for translational research currently 
exist within many pathology laboratories; indeed in the surgical pathology archives across the 
UK’s National Healthcare Service (NHS) vast numbers of FFPE tumour and non-tumour control 
samples are currently stored often untouched for a minimum of thirty years before disposal.  
There are contradictory opinions about the quality and quantity of nucleic acids that can be 
extracted from such collections of FFPE tissues and their potential use for downstream 
analysis. [9,10] Additionally, tissues released from NHS archives are less likely to be linked with 
clinical follow up data. However, these FFPE collections, when managed effectively can 
provide an excellent resource to be interrogated for biomarker discovery and validation 
procedures.  Innovative programmes can be established by biobanks to enhance their 
resources, in response to specific, scientifically valid and ethically approved requests from 
researchers, by engaging public hospitals to provide the biobank with access to defined 
cohorts of cancer tissues specifically for the creation of tissue microarrays (TMAs) and 
libraries of high quality nucleic acids extracted following standardised protocols.  Such 
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resources can be anonymised appropriately and made available in a timely manner for 
scientifically sound translational research activities.  Biobanks which are able to facilitate use 
of NHS pathology archives are ideally positioned to support specific cancer subtype research, 
in particular rare tumours of unmet needs; collections which would otherwise take decades 
to accumulate prospectively. 
Sample Quality: The discovery and validation of new biomarkers (diagnostic, prognostic, 
therapeutic or pharmodynamic) is also becoming dependent on the modern well-
standardised biobank. The regulatory and accreditation pathways that are required to 
establish a single biomarker as fit-for-purpose to progress through the many phases of 
development dictate that only tissue samples derived from biobanks with a high-level of 
quality assurance should be able to be utilised in such testing[11]. In this context the challenge 
for biobanking will be in the provision of the sample numbers that fulfil the required standards 
for testing.  Samples may therefore be required from more than one biobank and this will 
only be feasible if there is standardization in the protocols for sample collection, processing 
and storage within a biobank network.  The need for standardization and harmonization 
between biobanks in collecting, storing and providing tissue and clinical data for research was 
addressed in the UK by the National Cancer Research Institute’s Confederation of Cancer 
Biobanks (CCB) who published accreditation standards for all aspects of ‘Management’ and 
‘Sample’ quality in biobanking.[12] These standards also extended to biobank IT systems to 
facilitate interoperation and allow sharing of sample data at a national level.[13] More recently, 
the CCB has been tasked by the UK Tissue Coordination Centre to assist in the development 
of internationally recognised quality standards for biobanking in conjunction with BBMRI-
ERIC; a European wide infrastructure of biobanks and biomolecular resources[14].  
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Informatics: Biobanks require a dedicated mechanism for tracking samples in and out of the 
repository and for recording all stages of the sample journey from theatre, through pre-
analytical processing steps, storage and ultimately to distribution for approved research 
projects.  Ideally this should be an electronic tracking system accessible by key participants in 
the custody chain, and from different locations within the organisation including the ward, 
laboratory, office and biobank.  This can be made convenient through the use of web-based 
systems provided security and data integrity are maintained. However, the informatics 
capabilities of modern biobanks must also extend beyond just sample tracking and 
traceability.[15] Much of the success of a biobank will also depend on their ability to link 
samples to relevant and robust de-identified clinical, pathological and increasingly complex 
diagnostic molecular pathology information. This is critical as it allows researchers not only to 
further their understanding of tumour development and heterogeneity but to track the 
course of the disease including response to specific treatment regimens and final clinical 
outcomes.[16,17] This mandates that modern biobanks have appropriate informatics in place 
which are capable of operating across different software interfaces[18]. The biobank 
informatics system should be seen as an “integrated repository” of clinical and research 
information, facilitating collation of data sets from a variety of sources including clinical 
outcome data accessed through Cancer Registries, molecular test results (low and high 
throughput), data from national and international research programmes and hospital-based 
datasets all to form a single research IT platform. 
 
Gone are the days however of collating information through simple documents and 
spreadsheets; in their place exist complicated hybrid database architectures attached to 
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interrogative front-ends to facilitate the merger and interrogation of various datasets. An 
example of a successful biobank-integrative model is PICan, Pathology Integromics in Cancer, 
which marries this data capable biobank system to data analytics for researchers to 
warehouse information for data persistence and analyse in-situ[19]. The full capabilities of 
informatics synergistically leveraging Biobank capabilities are beyond the scope of this review 
and the authors would point to this perspective for added insight [20]. The current landscape 
of NGS that will allow data analytics from multiple modes (say RNA-seq: from gene-fusions, 
SNPs or differential expression) will require a dynamic architecture and strong database 
capabilities, perhaps even hybrid database models (MySQL, MongoDB and Neo4J). 
Established pipelines and controlled updates of annotations are important considerations to 
Biobanks where this information can also be archived on secure servers along with the raw 
files, such as fastq, that will allow data-mining in future studies. Access to such systems must 
be permission controlled with differentiating levels to allow researchers with the necessary 
approvals to see relevant information. 
 
Molecular diagnostics 
 
The assimilation of a molecular diagnostic service into research programmes with fully 
regulated biobanks is important for the following reasons: 
 
Genotyping: Clinical reference laboratories in academic medical centres are beginning to 
generate abundant genotypic data from samples undergoing various formats of NGS for 
mutations such as KRAS, EGFR or BRAF.  [5,21]  This information is not only useful for the 
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immediate management of the patient but also potentially for further discovery work on the 
same clinical sample in the future.  In order to test for mutations in specific genes such as 
KRAS, EGFR or BRAF to direct treatments, molecular diagnostic laboratories routinely extract 
nucleic acids from FFPE tissues.  Although molecular alterations can be detected at even low 
levels of tumour, many units providing molecular diagnostic services will require tumour 
samples to be sectioned and a Haematoxylin and Eosin (H&E) slide annotated so that the 
technologist undertaking the test can enrich the percentage of malignant nuclei available for 
molecular analyses. An accurate description of tumour cellularity within the invasive 
component of the tumour on the tissue section should be viewed as paramount to the overall 
evaluation of the molecular test result.[5]  
Increasing use of high throughput technologies, such as NGS platforms for targeted 
sequencing of exon coding regions or a subset of ‘genes of interest’ is an attractive proposition 
in both molecular research and molecular diagnostics[22] but will ultimately demand a greater 
ethical responsibility. Even with the use of targeted sequencing there is a possibility that 
incidental findings (IF) of clinical significance may arise; while return of IF may be less fraught 
in the context of a clinical molecular test there is a distinct lack of consensus about the 
management of IF in a research setting.[23] While debate about the ethical implications of NGS 
including consent and the ethical/moral obligation to return IF is outside the remit of this 
paper, it is nonetheless important to acknowledge particularly in integrated molecular 
pathology programme where the boundary lines between research and diagnostics may be 
blurred. [24] 
“Left-over” nucleic acid material: Increasingly so, molecular diagnostic laboratories are 
creating large collections of nucleic acids (both DNA and RNA) that are surplus to further 
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clinical need following molecular testing.  Such surplus samples if linked to clinical follow-up 
data and the results of diagnostic and therapeutic testing could be placed directly into an 
integrated Biobank for future research endeavours.  In addition the samples, coupled with 
the details of the annotation and the results of the molecular test, would remain available via 
the Biobank for validation of additional molecular diagnostic tests or service development 
programmes including those based on high through-put sequencing technologies.[22]  The 
samples would also be available to those translational research programmes which require 
samples to be collected, processed and stored to the highest standards of external 
accreditation for both diagnostic laboratories and biobanks. 
 Quality: Translational and clinical molecular research needs to be performed in a “laboratory 
quality framework” that will allow the transfer of such results into late stages of biomarker 
validation, clinical utility and licensing with little further downstream work. As a result, it is 
perceived that the processes of biobanking and translational molecular research are optimal 
when they are being undertaken in accredited laboratory environments. 
 
Molecular pathology research 
 
Molecular pathology research usually refers to two different but interconnected areas: 
research that can only be led by pathology investigators and research that requires a 
molecular pathology activity to be fully meaningful. The latter is self-explanatory: basic 
science discoveries require validation of the clinical relevance in an accredited laboratory. 
This clinical confirmation needs to be undertaken by those who understand the clinical 
samples, who can interpret the necessary clinico-pathological information (fundamental to 
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understanding the clinical relevance) and who can establish sound correlations between 
biology, phenotype and genotype. This is all within the realm of the molecular pathologist.  In 
reality precision medicine has fundamentally evolved from the application of predictive 
molecular pathology using analytical methods on high quality human samples to indicate the 
efficacy of a drug for an individual patient. 
 
There are research questions that can only be formulated from an in-depth knowledge of 
pathology. The archetype is the study of pre-neoplastic diseases. Only those that can 
recognise the phenotype of these tissue changes will be able to build the cohort of samples 
required to start the research process. As such the possible interactions between pathology 
and other disciplines allow the development of novel interface areas such as ‘pathology 
informatics’ or ‘molecular pathology epidemiology’.[25,26] Investigations of genes and gene 
products utilising well annotated, high quality samples from quality assured biobanks ensure 
a realistic, competitive time frame is created for the future development of novel diagnostics 
and therapeutic strategies in the overall goal of personalised medicine.  
 
 
Digital pathology 
 
Commercially available whole slide scanners can now rapidly generate high resolution digital 
images of entire tissue sections. This has a number of key advantages when integrated with 
biobanking and molecular pathology activities:  
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(i) Searchable digital images and sample selection: A digital image of the tissue can be 
recorded and stored as an integral part of the biobank information record for each tissue 
sample.  This creates a permanent searchable image archive available for review at any time.  
Biobank applicants given access to the digital slide images can select specific cohorts from a 
group of images. Digital review readily facilitates the quality control and annotation of the 
pathology within individual cases and ensures researchers request the correct samples for 
their specific research project.  Pathological review of the images can be carried out entirely 
on-line either locally or remotely using appropriate software, potentially removing the need 
to retrieve the glass slide for review by a pathologist [27]. 
 (ii) Digital sample annotation: Digital Pathology allows images to be digitally annotated and 
marked to highlight key tissue compartments and areas of interest.  For example, the 
boundaries of tumour within a tissue sample can be digitally traced on the image and stored 
for future studies that might require macro- or micro-dissection of FFPE samples.  Within 
biobanks digital annotation of regions of interest during TMA design and construction can 
help to facilitate the assessment of biomarker expression in future experiments using the 
TMAs. 
iii) Remote biomarker scoring: Digital pathology scans of research slides, including TMAs 
derived from biobanks break down many of the normal challenges associated with glass slides 
and provides flexibility and efficiency.[28] Novel tissue biomarkers can be rapidly viewed and 
scored on-line by pathologists or appropriately trained and competent scientists anywhere in 
the world, a key benefit for large multi-national, multi-site clinical trials or biomarker studies.  
Internet based access to digital pathology images can increase access to skilled pathologists 
for tissue review and biomarker evaluation even if they do not exist in one’s own organisation.   
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It is important to note that stringent ethical and governance regulations still apply for the use 
of digital scan cohorts that are held within biobanks for research.  Researchers must follow 
the same application processes to use stored scans for a specific purpose and then further 
amendments or new application is required if the scan sets are to be used for a secondary 
purpose. For example, a request for the use of archived biobank H&E scans to develop tumour 
cell recognition algorithms would need to fulfil the same ethical and governance 
requirements as a request for fresh H&E sections. 
 
Convergence and synergy: advantages of a fully integrated molecular pathology programme 
 
Advances in molecular diagnostics and the delivery of targeted cancer therapies require a 
dynamic partnership between academic researchers and pathologists or advanced 
practitioners with expertise in both tissue morphology and molecular pathology. A fully 
established molecular pathology programme, underpinned by a dedicated Biobank, 
integrated with a digital pathology operation, offers a complete ‘one stop’ environment to 
facilitate research collaborations at a local level, bringing academic and clinical staff together 
within one hybrid laboratory.  Such a unique hybrid environment consolidates manpower and 
equipment from healthcare and academia by amalgamating the technological capabilities of 
diagnostics and research.  
The partnership which develops in a hybrid environment encourages increased research 
productivity and efficiency as it enables the transfer of skills and knowledge, allowing 
healthcare and academia to benefit from the other’s expertise. This is illustrated in the 
example of biomarker science, where association between the two organisations is 
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considered essential to biomarker discovery and validation.[29] Collaboration enables 
researchers involved in biomarker science and clinicians involved in tissue procurement to 
collectively develop protocols and procedures which support acquisition of high quality, well 
defined biospecimens for use in biomarker research.  
It is widely documented that biobanks face significant challenges in terms of funding and 
resources to ensure long term sustainability.[30,31] Similarly, healthcare and academic 
institutions are currently facing unprecedented budget constraints and financial challenges.  
The creation of hybrid facilities presents a unique opportunity to overcome some of the 
mutual challenges faced by healthcare and academia organisations to avoid duplication of 
effort.[32]  Partnerships allow for shared use of laboratory equipment for tissue processing, 
tissue embedding, H&E staining and so forth, thus improving efficiency and lowering costs 
within both organisations. Integration of biobanking activities within a hybrid molecular 
pathology programme encourages the development of biomedical and clinical scientists with 
both clinical diagnostic and research expertise.  This convergence of skills and knowledge 
facilitates rapid transfer between molecular diagnostics in the clinical setting with scientific 
pursuits in the academic setting and vice versa.  Integrated Molecular Pathology programmes 
facilitate strong collaborations between academia, regulatory authorities and pharma. 
 
It is also important to highlight the increasing importance in liquid biopsies, based on 
academic research developments and the need to develop minimally-invasive 
diagnostics.[33,34,35]  Such liquid biopsies are reflective of the in vivo situation in the patient as 
opposed to a “segment” of the tumour;  as such they may allow for longitudinal analyses of 
patient responses to therapies without the need for costly, painful invasive procedures.  
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Progressive solid tumour biobanks, working in close collaboration with molecular pathology 
programmes, are ideally situated to develop and standardize the pre-analytical 
methodologies required for acquisition of quality assured liquid biopsy samples for the 
validation of tests on circulating biomarkers (i.e. circulating free DNA, microRNAs, exosomes 
or microvesicles, circulating tumour cells) from many tumour types.   
 
The Northern Ireland Model 
 
All the considerations for a modern, integrated and synergistic molecular pathology 
programme have been taken into account when designing the Northern Ireland Molecular 
Pathology Laboratory.  A key element of this programme is the integration of a biobank with 
the primary aim of moving beyond the classic collection of biological samples and associated 
clinical information, to become a true repository that involved the scientific results generated 
by the different collaborators and users.  The Northern Ireland Biobank (NIB) has full ethical 
approval for the collection, storage and distribution of tumour and non-tumour control tissue 
and associated bio-samples to support translational research programmes regionally and 
beyond.  Key components of the NIB model such as unique identifiers for samples linked to 
the consented patient, tissue proformas completed by consultant histopathologists and 
archives of digital images (macroscopic and microscopic) are outlined in Figure 2.  
 
Established as a joint venture between Queen’s University Belfast (QUB) and the Belfast 
Health and Social Care Trust (BHSCT), the NIB has become fully integrated into the newly 
restructured molecular pathology programme within the University’s designated cancer 
research facility, the Centre for Cancer Research and Cell Biology (CCRCB).  This new molecular 
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pathology department has been purposely designed in partnership with the BHSCT pathology 
laboratories to create a hybrid diagnostic and translational research operation, underpinned 
by the NIB.  As well as integration within a molecular pathology programme, the NIB has 
distinct advantages including: 
- Ethical approval for the prospective collection, storage and distribution of cancer 
tissues and related biospecimens to researchers 
- Ethical approval to access tissue samples in the Belfast Health and Social Care Trust 
pathology surgical archives including surplus DNA or RNA from Molecular Diagnostics  
- Established relationships with the Clinical Care teams and the Northern Ireland Cancer 
Registry for the acquisition of de-identified clinical and pathological information 
associated with NIB samples 
- A secure information management system which incorporates digital imaging of NIB 
tissue samples 
- Facility for analysis of Tissue Microarrays – a TMA Toolbox 
 
Challenges for the future 
 
The fully integrated molecular pathology programme of which the Northern Ireland Biobank 
is an integral component offers a complete end to end molecular diagnostic and translational 
research operation.  This co-operative effort of biobanking, molecular diagnostics, 
translational research and digital pathology has the potential to deliver real improvements in 
the clinical management of cancer.  The rapidly changing face of sample requirements for 
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molecular diagnostics, emerging technologies or for new research paradigms e.g. cfDNA or 
Circulating Tumour cells require biobanks to continuously review and adapt their own 
collection protocols. The Northern Ireland Biobank which is fully integrated within a 
diagnostic and research molecular pathology environment is ideally suited to promptly create 
and quality control these new sample collections to provide the high quality sample collection 
for clinical validations or researchers.  
Furthermore and moving forward, there is a need to exploit the collective resources of 
biobanks and harness the knowledge generated from individual molecular pathology 
programmes to continue to drive and improve cancer diagnostics and research.  Work has 
already begun in Europe and North America to address the practicalities of integrating 
biobanks into larger networks with shared informatics.[36] However, many legal and ethical 
challenges still exist to such integration. 
 
Summary 
 
It is our opinion that modern research will need to be driven by key new paradigms: clinical 
utility, long-term affordability and high-end integration. The consequence of this is clear: we 
need a new paradigm for the integration of molecular diagnostics, biomarker validation and 
biomarker discovery. This integrated paradigm must be led by molecular pathology 
programmes with biobanking as a critical component of the overall process. 
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Box 1: What defines a High Quality FFPE tumour Tissue Sample? 
- Full clinical details 
- Full pathology report availability 
- Cold ischaemia time 
- Fixation type and time 
- Processing and storage history 
- Full pathological annotation: 
  % tumour 
  % normal 
  % necrosis 
- Availability of quality assurance data 
- Matching normal samples available 
- Searchable H&E scan availability 
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